Tuesday, May 5-Thursday, May 7
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
Posts
#ClinicalTrial EA7211/STRASS 2, led in the US by @kencardonaMD, is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: https://bit.ly/EA7211
EA1241, led by @jsparano of @MountSinaiNYC, is a companion study for patients who previously took part in either the TAILORx or RxPONDER #BreastCancer trials. Learn more: https://bit.ly/EA1241 #bcsm
Thank you @eaonc for continuing to inform us on results of your #ClinicalTrials - pushing science forward and honoring research volunteers.
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
33
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
